Comparative Pharmacology
Head-to-head clinical analysis: MEPRON versus NITAZOXANIDE.
Head-to-head clinical analysis: MEPRON versus NITAZOXANIDE.
MEPRON vs NITAZOXANIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
It is a hydroxynaphthoquinone that selectively inhibits mitochondrial electron transport chain in Plasmodium species, specifically at the cytochrome bc1 complex (Complex III), leading to collapse of mitochondrial membrane potential and inhibition of pyrimidine synthesis.
Interferes with pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reactions, essential for anaerobic metabolism in certain pathogens.
750 mg orally twice daily with food for 21 days for treatment of mild-to-moderate Pneumocystis jirovecii pneumonia. For prophylaxis: 1500 mg orally once daily with food.
500 mg orally twice daily for 3 days for treatment of diarrhea caused by Cryptosporidium parvum or Giardia lamblia; for chronic giardiasis, 500 mg twice daily for 10 days.
None Documented
None Documented
Mean terminal elimination half-life is 2.2-3.2 days (approximately 53-77 hours) in adults; prolonged in hepatic impairment (up to 22 days) and in elderly (up to 5 days).
The terminal elimination half-life of the active metabolite tizoxanide is approximately 1.5–2 hours in adults and 2–4 hours in children. Clinical context: The short half-life supports twice-daily dosing; accumulation is minimal with normal dosing intervals.
Primarily fecal (87-94%) via bile; renal excretion accounts for <1% as unchanged drug. A minor metabolite, atovaquone glucuronide, is excreted in urine.
Nitazoxanide is primarily excreted in feces (approximately 66%) and urine (approximately 33%). Renal elimination accounts for about 33% of the dose, primarily as the active metabolite tizoxanide (glucuronide conjugates), while fecal excretion accounts for approximately 66%, mostly as tizoxanide and its conjugates.
Category C
Category A/B
Antiprotozoal
Antiprotozoal